• News and Announcements


    Vigene Biosciences announces partnership with Virovek to make high yield cGMP AAV production technology accessible and affordable.

    ROCKVILLE, Md., Apr. 16, 2018 Vigene Biosciences, Inc. (Vigene), a leading biotechnology company for viral vector production and development, announced today that the company is partnering with Virovek to utlize its proprietary AAV Production Technology, BAC-to-AAV, in AAV GMP productions. This technology utilizes the baculovirus expression system to produce AAV vectors in insect cells under serum-free condition. AAV produced from BAC-to-AAV has been proven to infect and transduce a myriad of mammalian cells in vivo and in vitro. Read More

    Vigene Biosciences Partners with The Michael J. Fox Foundation to Distribute Alpha-synuclein Knockdown Viral Vectors for Parkinson’s Disease Research

    ROCKVILLE, Md., Nov. 7, 2017  Vigene Biosciences, Inc. (Vigene), a leading biotechnology company for viral vector production and development, today announced a collaboration with The Michael J. Fox Foundation for Parkinson's Research (MJFF) for AAV repository and domestic production. Viral vectors to knockdown mouse or human alpha-synuclein (aSyn) will be made available for purchase in early 2018. Read More

    Vigene Biosciences and Mila’s Miracle Foundation announce partnership on Gene therapy for CLN7 Batten Disease

    ROCKVILLE, Md., Nov. 1, 2017 Vigene Biosciences, Inc. (Vigene), a leading biotechnology company for clinical and research-grade viral vector production and development, announces a partnership with Mila’s Miracle Foundation (MMF) to manufacture recombinant adeno-associated virus (rAAV) needed to advance clinical trials for CLN7 Batten Disease. Read More

    Vigene Biosciences Acquires the cGMP Manufacturing Facility and Assets of Omnia Biologics

    ROCKVILLE, Md., Nov. 29, 2016 /PRNewswire/ -- Vigene Biosciences, Inc. (Vigene), a leading biotechnology company for viral vector production and development, announced today that the company has entered into a definitive agreement to acquire the assets of Omnia Biologics, Inc. (Omnia), including Omnia's cGMP facility and equipment. Read More